Sophiris Bio Inc. | Mutual Funds
Mutual Funds that own Sophiris Bio Inc.
Vanguard Total Stock Market Index Fund
718,437
2.39%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
559,915
1.86%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
135,492
0.45%
0
0%
07/31/2018
iShares Micro Cap ETF
77,603
0.26%
0
0.02%
09/06/2018
Fidelity Spartan Total Market Index Fund
57,410
0.19%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
44,768
0.15%
0
0%
07/31/2018
Vanguard Balanced Index Fund
25,141
0.08%
0
0%
07/31/2018
Fidelity Nasdaq Composite Index
19,042
0.06%
0
0%
07/31/2018
7,327
0.02%
0
0.08%
09/05/2018
Vanguard Invt. Fds. ICVC - US Equity Index Fund
6,675
0.02%
6,675
0%
06/30/2018
| Address |
1258 Prospect Street
La Jolla California 92037
United States
|
|
Employees
|
- |
| Website |
http://www.sophirisbio.com |
| Updated |
07/08/2019 |
| Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. It is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. |
